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INTRODUCTION
The burden of hepatitis B virus (HBV) infection continues to increase worldwide despite widespread awareness of preventive measures, including the availability of a safe and effective vaccine. 1 The World Health Organization estimates that 2 billion people worldwide have serologic evidence of past or present HBV infection, and 360 million people are chronically infected and at-risk for HBV-related liver disease. 2 Most of these people are in the developing world where intermediate (2-8% and 15-40%) to high (> 8% and > 40%) endemic areas (based on prevalence of hepatitis B surface antigen [HBsAg] and total antibodies to hepatitis B core antigen [anti-HBc], respectively) have been recognized, mostly reflecting people becoming horizontally infected during childhood through mechanisms not fully understood. In almost all Amerindian communities of the Amazon Basin and certain areas of the Andes in Peru, high rates of chronic HBV infection have been described [3] [4] [5] with associated high morbidity and mortality rates. [6] [7] [8] [9] [10] Persons with chronic HBV infection (defined as those with serologic evidence of HBsAg for a period of at least 6 months) are the major reservoir for transmission, although any HBsAgpositive person is potentially infectious. 1 Hepatitis B virus is efficiently transmitted by sexual contact, 11, 12 and sex partners of chronically infected persons have been shown to have a higher prevalence of HBV infection than control populations that included household (non-sexual) contacts with infected persons. 13 In Peru, both human immunodeficiency virus (HIV-1) and sexually transmitted infections (STI) have disproportionately affected men who have sex with men (MSM), in whom high rates of HIV-1, STI, and risky sexual behavior have been reported in major urban and populated cities. 14 In this setting, injecting drug use (IDU) is largely uncommon, and HBV transmission is largely facilitated by high-risk sexual behavior.
The epidemiology of HBV infection, as it is related to risky sexual behavior, HIV-1 infection, or STI, has not been welldefined among MSM in Peru. A better understanding of the magnitude and risk factors for HBV infection among MSM is necessary to better formulate appropriate intervention strategies for its control. We assessed the prevalence and associated risk factors for past HBV infection among participants of a second generation HIV-1 sentinel surveillance conducted among MSM of six major urban cities during the period of October 2002 through March 2003.
MATERIALS AND METHODS

Study population and procedures. Between October 2002
and March 2003, during a 3-month period at each city, we conducted a cross-sectional sentinel surveillance survey in six different Peruvian cities: Lima, Sullana, Piura (coast), Arequipa (highlands), Iquitos and Pucallpa (Amazon jungle, endemic for HBV infection). Men who were at least 18 years of age and who had sexual intercourse with at least one man during the previous year were eligible to participate. 14 
RESULTS
Of 3,280 MSM participating in the sentinel surveillance, 2,703 (82.4%) consented to specimen storage and future testing of samples. All of them had samples available for HBsAg testing, and 2,683 (99.3%) had samples for anti-HBc testing. Compared with men consenting to specimen storage, non-consenting men were more likely to be from Lima than from other cities, be older, report higher education level, report symptoms of STI in the preceding year, practice commercial sex work, be either of an anal receptive or versatile nature (both anal receptive and insertive) in their sexual role, and have more known HIV-1-positive male sex partners and fewer female sex partners in the preceding 3 months as well as sustain higher antecedent HIV-1 and HSV-2 infection (data not shown).
Overall, the crude anti-HBc and HBsAg prevalences were 22.3% and 3.2%, respectively. Age-and HIV-standardized prevalences of 20.2% and 2.8%, respectively, were noted ( Table 1 ). The prevalence of HBV serologic markers differed by city and HIV-1 serostatus; in general, HIV-1-infected men had significantly higher prevalences of anti-HBc and HBsAg ( Table 2 ). Serologic evidence of HBeAg was documented in 15 (34.1%) of 43 HBsAg-positive men with available samples and was also found to be significantly higher among 13 HIV-1-infected (61.5%) compared with 30 HIV-1-uninfected (23.3%) men ( P = 0.034).
Selected demographic and sexual behavior characteristics of men under study are described in Table 3 . Of note, only 17 (0.6% of the total study participants) of 92 men with previous HIV-1 positive tests were receiving any type of antiretroviral treatment (no details about the kind of treatment were obtained). Only three men reported any type of IDU behavior in the preceding 3 months. A direct, age-related increase in anti-HBc seroprevalence was noted, being lowest (10.9%) among those 20 years of age or less and highest (46.3%) among those 41-50 years of age ( P < 0.001; χ 2 test for trend) ( Figure 1 ).
Men with anti-HBc positive results were more likely to be older, report lower educational level, self-identify as Anti-HBc = antibodies to hepatitis B core antigen; HBsAg = hepatitis B surface antigen; N = number of participants tested; n = number of participants positive; % = percentage; 95% CI = 95% confidence interval.
* Standardized by age and HIV-1 serostatus.
homosexuals or transvestites, practice commercial sex work, and report being mainly either of an anal receptive or versatile nature in their sexual role. There were no differences in the proportion of men reporting STI symptoms in the preceding year, although symptoms of anal abnormalities, including warts (4.7% versus 2.3%; P = 0.005), spontaneous secretion (3.4% versus 1.3%; P = 0.002), spontaneous bleeding (3.9% versus 2.1%; P = 0.022), spontaneous pain (3.4% versus 1.3%; P = 0.003), and bleeding during sex or defecation (8.2% versus 4.1%; P < 0.001) were more frequently reported at screening, as well as more frequently evidenced during physical examination, including warts (4.9% versus 2.4%; P = 0.004), spontaneous secretion (2.9% versus 1.3%; P = 0.013), and hemorrhoids (7.9% versus 3.1%; P < 0.001).
More male and less female sex partners (including less female partners with HIV-1-negative and unknown HIV status) in the last 3 months were significantly reported by these men ( Table 3 ). There were no differences in the types of partnership (primary, occasional, or one-night stand) or in the partner-specific sex behavior (insertive or receptive and protected or unprotected anal intercourse) established with up to the preceding three sex partners (data not shown) with the exception of insertive anal intercourse, which was less frequently reported by anti-HBc-positive men (37.8% versus 43.9%; P = 0.008). HBsAg-positive men were more likely to identify themselves as transvestites, report being engaged in commercial sex work ( Table 3 ) , and report sustained rectal bleeding or discharge during the previous year (13.3% versus 5.5%; P = 0.007). No differences in STI symptoms reported at screening by HBsAg status were noted (data not shown); however, a higher proportion of generalized lymph node enlargement (9.5% versus 2.2%; P < 0.001), anal warts (7.1% versus 2.9%; P = 0.041), and hemorrhoids (9.5% versus 4.0%; P = 0.023) were found at physical examination among HBsAg-positive men. No differences in the median number of male and female sex partners were observed. HBsAg-positive men also reported more frequent sex with HIV-1-positive partners ( Table 3 ) .
There were no differences in these data for participants who reported having traveled to other Peruvian cities or countries during the previous 12 months, including when they reported sexual behavior with men or women at these places. Additionally, there were no differences in terms of alcohol or drug use (including before or during sex) in the preceding 3 months, regardless of anti-HBc or HBsAg serostatus (data not shown).
HIV-1 infection, syphilis, and HSV-2 infection were also more frequently diagnosed among men with positive hepatitis B serologic markers ( Table 3 ).
In the multivariate analyses and after adjustment by city of residence and educational level, serologic evidence of total anti-HBc was more likely to occur in those who were older, reporting versatile sexual role, receiving money/gifts in exchange for sex, and having a previous diagnosis of syphilis, HIV-1, or HSV-2 infection and less likely among those reporting having had sex with women in the preceding 3 months. Participants with HBsAg-positive results were also more likely to have findings of generalized lymph node enlargement at physical examination as well as an HIV-1 diagnosis ( Table 4 ) .
DISCUSSION
To our knowledge, this is the first study to examine the prevalence of and associated risk factors for pre-existing HBV infection among MSM in Peru, a population where IDU is almost non-existent. After standardization for age and city of residence, evidence of total anti-HBc, suggesting previous exposure to or infection by HBV, was noted in one-fifth of study participants, whereas only 2.8% of them had results suggesting either an acute, resolving, or chronic stage (HBsAg seropositivity). Older age, versatile sexual role, receiving money/gifts in exchange for sex, syphilis, HIV, and HSV-2 infection were independently associated with total anti-HBc, characteristics which suggest HBV acquisition by sexual exposure. The prevalence of anti-HBc also increased significantly with age, reaching a peak at age 50, also supporting sexual exposure as the predominant mode of HBV acquisition. HIV infection and generalized lymph node enlargement were associated with HBsAg seropositivity in this study, which has a biologic correlate with decreased HBV clearance mechanisms as consequence of HIV-induced immunodeficiency. In particular, among non-Amazon jungle cities, the prevalence of HBV markers found in this study seems to be higher than those observed in the general population based on studies conducted in young pregnant women and blood donors. 15 This study is also the first to provide objective and quantifiable information on the prevalence of HBV serologic markers among HIV-1-infected MSM in Peru, which, in general does not differ from data observed in other high-risk settings. 16, 17 Surprisingly, HIV-1-infected MSM living in Amazon river basin jungle cities had similar levels of HBsAg seropositivity as corresponding HIV-1-uninfected men, suggesting resolved HBV infection occurrences at earlier ages that may have preceded HIV infection or a lack of study power to detect such differences. Negligible rates of antiretroviral treatment coverage among HIV-1-infected participants by the time that this study was conducted do not seem to have affected the generalization of our observed prevalence. Worldwide, homosexual men exhibit higher rates of HBV infection than most other at-risk groups such as commercial sex workers or heterosexual men. Indeed, high levels of HBV infection have been found in different MSM communities, and these levels have been associated with lifetime number of sexual partners, unprotected intercourse, HIV-1 infection, IDU behavior, and history of STI among other factors. [18] [19] [20] [21] [22] [23] [24] [25] Given shared routes of transmission, high rates of active HBV infection among HIV-1-infected participants would have a detrimental impact on the epidemiology of HBV in the context of expected prolonged periods of infectivity based on high HBeAg prevalences. 26 Treatment targeting both active viruses would reverse this impact and improve health conditions of the affected population. 27 Our study suffered from several limitations. First, its design did not permit us to differentiate between incident (acute) and chronic HBV infection through concurrent anti-HBc and HBsAg serologic testing, which would have had important implications to predict the burden of disease and subsequent management of complications (e.g., liver cirrhosis, hepatocellular carcinoma, etc.). This constitutes the main limitation of the study. If only 2.8% (95% CI = 2.2-3.6%) of the general MSM population, but not the HIV-1-infected subpopulation (9.5%; 95% CI = 6.3-12.6%), has an acute or resolving HBV infection based on HBsAg seropositivity, then the potential burden of disease would be lower than we might have thought; however, our study likely underestimated the prevalence of HBV serologic markers (and associated factors as well), because non-consenting participants for further testing from the parent study had higher risk behaviors and STI rates and were more likely to have had HBV serologic positive markers. Second, although a large study on a nationwide basis, cityspecific prevalence estimates could have been more accurately defined had there been larger sample sizes in certain cities; this would have allowed for more accurate prevalence estimates with narrow confidence intervals and more statistical power for the assessment of associated factors for HBV serologic marker positivity. Also, no analysis to assess the relationship with lifetime sexual exposure was conducted, because risk-behavior assessment was restricted to the preceding 3 months; however, HBV infection has been associated with both lifetime sexual exposure and risk behavior. 28 Third, we did not obtain information regarding HBV preventive vaccination coverage or other important and often frequent modes of HBV acquisition, such as antecedent surgeries, blood transfusions, history of unsafe injections, tooth extractions, intravenous catheterization, piercing, bloodletting, or tattooing practices. Thus, accounting for these potential confounding variables could not be done. Lastly, the evaluation of the distribution of HBV genotypes and phylogenetic analysis of HBV strains was not performed because of funding limitations. This type of molecular genetic analysis among HBV-infected participants would have allowed us to much better estimate the severity of the HBV epidemic in this MSM population, where previously, genotype F was found to predominate. 29 Since 2003, the Ministry of Health of Peru has been providing universal HBV vaccination to all children less than 1 year of age, and in 2008, they implemented a nationwide campaign targeting the population at large. However, populations at high risk for STI acquisition and/or transmission, such as MSM, have not been specifically targeted and deserve further special emphasis. Short-course vaccination regimens seem to reach acceptable coverage, 30, 31 especially among mobile populations, like commercial sex workers 32 or groups with high rates of migration. Determination of HBV antibody levels after vaccination in HIV-1-infected patients may also be warranted given concerns of effectiveness. 33, 34 Continued educational efforts, creation of environments that facilitate proper risk-factor evaluation and testing, and access to low-cost vaccine may facilitate vaccine uptake 35 in these populations. To increase acceptance, patients less health-motivated should be identified for pre-vaccination counseling, 36 and innovative means of ensuring completion of vaccination need to be developed. 37 It has been shown that hepatitis B vaccination can be integrated into STD clinic services with reasonable levels of vaccine acceptance and series completion. 38 In summary, a high prevalence of HBV serologic markers suggesting previous exposure to or natural infection was found to be high among Peruvian MSM and was also found to be associated with high-risk sexual behavior, syphilis, HIV-1, and HSV-2 infection, suggesting sexual contact as a main mode of transmission. Given the potential likelihood of HBV acquisition and transmission, MSM in Peru constitute a target population for further HBV preventive interventions. These should include STI screening and treatment, effective and affordable programs for HBV vaccine delivery for susceptible individuals, and risk-reduction counseling and/or treatment of chronically infected individuals. Tracking the dynamic of the epidemic in non-intervened MSM at-risk groups is needed to continue to monitor trends in incidence and changes in circulating genotypes that may be of relevance in terms of treatment strategies. In the context of high rates of co-infection in this setting, HBV testing needs to be a priority among HIV-1-infected MSM to more appropriately lead the selection and monitoring of antiretroviral treatment schemes.
